KR20180035785A - Nut 중간선 암종의 치료 - Google Patents

Nut 중간선 암종의 치료 Download PDF

Info

Publication number
KR20180035785A
KR20180035785A KR1020187000569A KR20187000569A KR20180035785A KR 20180035785 A KR20180035785 A KR 20180035785A KR 1020187000569 A KR1020187000569 A KR 1020187000569A KR 20187000569 A KR20187000569 A KR 20187000569A KR 20180035785 A KR20180035785 A KR 20180035785A
Authority
KR
South Korea
Prior art keywords
alkyl
alkylene
cycloalkyl
aryl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020187000569A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 비. 랜다우
마이클 에이치. 카게이
Original Assignee
텐샤 세러퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 텐샤 세러퓨틱스 인코포레이티드 filed Critical 텐샤 세러퓨틱스 인코포레이티드
Publication of KR20180035785A publication Critical patent/KR20180035785A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G01N33/57407—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G01N2333/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020187000569A 2015-06-26 2016-06-24 Nut 중간선 암종의 치료 Withdrawn KR20180035785A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562185203P 2015-06-26 2015-06-26
US62/185,203 2015-06-26
PCT/US2016/039270 WO2016210275A1 (en) 2015-06-26 2016-06-24 Treatment of nut midline carcinoma

Publications (1)

Publication Number Publication Date
KR20180035785A true KR20180035785A (ko) 2018-04-06

Family

ID=56409188

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187000569A Withdrawn KR20180035785A (ko) 2015-06-26 2016-06-24 Nut 중간선 암종의 치료

Country Status (14)

Country Link
US (1) US20180193350A1 (https=)
EP (1) EP3314005A1 (https=)
JP (1) JP2018520124A (https=)
KR (1) KR20180035785A (https=)
CN (1) CN107787227A (https=)
AR (1) AR105124A1 (https=)
AU (1) AU2016283020A1 (https=)
BR (1) BR112017028178A2 (https=)
CA (1) CA2989313A1 (https=)
HK (1) HK1252062A1 (https=)
IL (1) IL256186A (https=)
MA (1) MA42249A (https=)
MX (1) MX2017016337A (https=)
WO (1) WO2016210275A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2902030T3 (pl) 2010-05-14 2017-07-31 Dana-Farber Cancer Institute, Inc. Związki tienotriazolodiazepinowe do leczenia nowotworu
MX354217B (es) 2010-05-14 2018-02-19 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
CA2929652A1 (en) 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
SG11201607108XA (en) 2014-02-28 2016-09-29 Tensha Therapeutics Inc Treatment of conditions associated with hyperinsulinaemia
BR112017008714A2 (pt) 2014-10-27 2017-12-19 Tensha Therapeutics Inc inibidores de bromodomínio
EP4629984A1 (en) * 2022-12-06 2025-10-15 BioVentures, LLC Development of potent dual hdac/brd4 inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
WO2009084693A1 (ja) 2007-12-28 2009-07-09 Mitsubishi Tanabe Pharma Corporation 抗癌剤
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
ES2563057T3 (es) 2009-11-05 2016-03-10 Glaxosmithkline Llc Inhibidor de bromodominio de benzodiazepina
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
RS54645B1 (sr) 2009-11-05 2016-08-31 Glaxosmithkline Llc Benzodiazepin kao inhibitor bromodomena
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
PL2902030T3 (pl) * 2010-05-14 2017-07-31 Dana-Farber Cancer Institute, Inc. Związki tienotriazolodiazepinowe do leczenia nowotworu
JP5715241B2 (ja) * 2010-05-14 2015-05-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法
US9085582B2 (en) 2010-06-22 2015-07-21 Glaxosmithkline Llc Benzotriazolodiazepine compounds inhibitors of bromodomains
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012151512A2 (en) 2011-05-04 2012-11-08 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2721031B1 (en) 2011-06-17 2016-01-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
SG11201607108XA (en) 2014-02-28 2016-09-29 Tensha Therapeutics Inc Treatment of conditions associated with hyperinsulinaemia

Also Published As

Publication number Publication date
EP3314005A1 (en) 2018-05-02
HK1252062A1 (zh) 2019-05-10
IL256186A (en) 2018-02-28
US20180193350A1 (en) 2018-07-12
AU2016283020A1 (en) 2018-01-04
JP2018520124A (ja) 2018-07-26
BR112017028178A2 (en) 2018-08-28
MX2017016337A (es) 2018-11-22
AR105124A1 (es) 2017-09-06
CN107787227A (zh) 2018-03-09
WO2016210275A1 (en) 2016-12-29
MA42249A (fr) 2018-05-02
CA2989313A1 (en) 2016-12-29

Similar Documents

Publication Publication Date Title
KR20180035785A (ko) Nut 중간선 암종의 치료
RU2566821C2 (ru) Модулятор nmda-рецептора со стабилизированной вторичной структурой и его применение
EA038337B1 (ru) Ингибиторы ezh2 для лечения лимфомы
CA2943213C (en) Aripiprazole formulations having increased injection speeds
JP2013544260A (ja) Ｊａｋ２で投薬治療された状態の治療
KR20120129954A (ko) ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
EP2694073B1 (en) Combinations of akt and mek inhibitors for treating cancer
JP2018535939A (ja) Ｎａｓｈ関連肝臓癌を治療するためのｅｐ４受容体拮抗薬の使用
WO2008115443A1 (en) Kinase protein binding inhibitors
AU2014361814A1 (en) Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders
US11872220B2 (en) Methods and compositions for treating B-cell malignancies
JP7590084B2 (ja) 癌治療のためのｃｘｃｒ７阻害剤
JP2009537626A (ja) ９−ヒドロキシエリプチシン誘導体による悪性表現型の復帰変異
WO2022122668A1 (en) Combined inhibition of amino acid transporters for inhibiting human plasmacytoid dendritic cell activity during autoimmunity
JP2025537524A (ja) Ｅｐｈ－エフリン四量体化に拮抗し、双方向シグナル伝達を阻害する低分子量化合物
CN110872341B (zh) 一种靶向fgfr1的拮抗短肽
EP4008330A1 (en) Combined inhibition of amino acid transporters for inhibiting human plasmacytoid dendritic cell activity during autoimmunity
EP4117660B1 (en) Methods of modulating t-cell activation and treating chronic heart failure using carboranes
US12152008B2 (en) Cyclopentaimidazolones for the treatment of cancer
RU2808667C2 (ru) Ингибиторы cxcr7 для лечения рака
WO2026006503A9 (en) Compounds as nlrp3 pet radiotracers and compositions and uses thereof
KR100840686B1 (ko) 헤테로고리를 포함하는 카보닐구아니딘 유도체를유효성분으로 함유하는 ｂａｆｆ 매개성 질환의 예방 및치료용 약학적 조성물
HK40105387A (zh) 用於治疗红细胞增多症的组合物和方法
HK40016954A (en) Combinations of akt and mek inhibitor compounds, and methods of use
NZ617243B2 (en) Combinations of akt and mek inhibitor compounds, and methods of use

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000